| Molecular formula | C50H68N14O10 |
|---|
| Molecular weight | 1025.2 g/mol |
|---|
| Registered trials | 4 |
|---|
| PubChem CID | 9941379 |
|---|
What PT-141 Is
PT-141, also known as bremelanotide, is a synthetic peptide compound identified by PubChem CID 9941379, with a molecular formula of C50H68N14O10. It has no FDA-approved drug label under this profile. This means there is no established indication, dosing standard, or manufacturer-provided safety information to report here.
Regulatory Status
PT-141 is classified as an unapproved research compound. Any use outside of registered clinical research falls outside FDA oversight, and no approved product label exists for it in the data reviewed.
Trial Footprint
There are 4 registered clinical trials associated with this compound. Available trial records include studies conducted under the name bremelanotide in women with female sexual arousal disorder and hypoactive sexual desire disorder. One completed trial (NCT01382719) examined bremelanotide in premenopausal women with these conditions. A separate completed trial (NCT02338960) evaluated bremelanotide in premenopausal women with hypoactive sexual desire disorder. Another completed trial (NCT00425256) assessed safety and efficacy in women with female sexual arousal disorder. These records describe trial activity only and do not establish that the compound is safe or effective for any use.
FAQ
No. PT-141 is classified as an unapproved research compound, and no FDA-approved label exists for it under this profile. Any registered trials studying related compounds do not equate to approval for general use.
PT-141 is also referred to as bremelanotide in clinical trial records. It is identified chemically by PubChem CID 9941379.
The data reviewed shows 4 registered clinical trials associated with this compound. Several of these trials, listed under the name bremelanotide, focused on female sexual arousal disorder and hypoactive sexual desire disorder.
Completed trials examined bremelanotide in premenopausal women with hypoactive sexual desire disorder and in women with female sexual arousal disorder. These studies assessed safety and efficacy outcomes but are part of a research record, not an approved use.
No adverse event report data was available in the dataset reviewed for this compound.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem CID 9941379 ClinicalTrials.gov
Updated 2026-09-19